1
|
Agnes M, Mazza A, Malanga M, Manet I. Sculpturing the future of water-soluble cyclodextrin branched polymers in pharmaceutical applications. J Mater Chem B 2024; 12:7969-7976. [PMID: 39091229 DOI: 10.1039/d4tb01165a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/04/2024]
Abstract
Water-soluble polymers of cyclodextrins (CyD) can be easily obtained in alkaline media following polycondensation of the naturally occurring monomers in the presence of a crosslinking agent. They can be further modified to customize specifically functionalized architectures. Compared to other macromolecules natural and not, the CyD polymers are endowed with a unique feature, the cone-shaped cavities where they can host guests of various nature. This element has sollicited interest in this class of molecules for a wide range of applications including the biomedical field, in particular drug delivery. The CyD polymers display excellent behavior in terms of water solubility and solubilizing power towards drugs and therapeutic agents that are incompatible with biological fluids. Moreover, they can load more than one type of therapeutic agent in a single system thus allowing to implement combination therapy. In spite of some very promising results as delivery systems, their potentialities remain limited by some intrinsic hurdles. Herein, we comment on their limits mainly related to the production process and the possible solutions to overcome them, giving an outlook on their assets for innovation in disease treatment.
Collapse
Affiliation(s)
- Marco Agnes
- Consiglio Nazionale delle Ricerche (CNR), Istituto per la Sintesi Organica e la Fotoreattività (ISOF), Via Gobetti 101, 40129 Bologna, Italy.
| | - Arianna Mazza
- Consiglio Nazionale delle Ricerche (CNR), Istituto per la Sintesi Organica e la Fotoreattività (ISOF), Via Gobetti 101, 40129 Bologna, Italy.
| | - Milo Malanga
- CarboHyde Zrt., Berlini str., 47-49, Budapest, 1045, Hungary
| | - Ilse Manet
- Consiglio Nazionale delle Ricerche (CNR), Istituto per la Sintesi Organica e la Fotoreattività (ISOF), Via Gobetti 101, 40129 Bologna, Italy.
| |
Collapse
|
2
|
Anderson AM, Manet I, Malanga M, Clemens DM, Sadrerafi K, Piñeiro Á, García-Fandiño R, O'Connor MS. Addressing the complexities in measuring cyclodextrin-sterol binding constants: A multidimensional study. Carbohydr Polym 2024; 323:121360. [PMID: 37940263 DOI: 10.1016/j.carbpol.2023.121360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Revised: 08/22/2023] [Accepted: 08/30/2023] [Indexed: 11/10/2023]
Abstract
A class of cyclodextrin (CD) dimers has emerged as a potential new treatment for atherosclerosis; they work by forming strong, soluble inclusion complexes with oxysterols, allowing the body to reduce and heal arterial plaques. However, characterizing the interactions between CD dimers and oxysterols presents formidable challenges due to low sterol solubility, the synthesis of modified CDs resulting in varying number and position of molecular substitutions, and the diversity of interaction mechanisms. To address these challenges and illuminate the nuances of CD-sterol interactions, we have used multiple orthogonal approaches for a comprehensive characterization. Results obtained from three independent techniques - metadynamics simulations, competitive isothermal titration calorimetry, and circular dichroism - to quantify CD-sterol binding are presented. The objective of this study is to obtain the binding constants and gain insights into the intricate nature of the system, while accounting for the advantages and limitations of each method. Notably, our findings demonstrate ∼1000× stronger affinity of the CD dimer for 7-ketocholesterol in comparison to cholesterol for the 1:1 complex in direct binding assays. These methodologies and findings not only enhance our understanding of CD dimer-sterol interactions, but could also be generally applicable to prediction and quantification of other challenging host-guest complex systems.
Collapse
Affiliation(s)
- Amelia M Anderson
- Cyclarity Therapeutics, 8001 Redwood Blvd Novato, CA 94945, USA; Departamento de Física Aplicada, Facultade de Física, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Departamento de Química Orgánica, Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, Campus Vida s/n, E-15782 Santiago de Compostela, Spain
| | - Ilse Manet
- Istituto per la Sintesi Organica e la Fotoreattività (ISOF), Consiglio Nazionale delle Ricerche (CNR), via P. Gobetti 101, Bologna 40129, Italy
| | - Milo Malanga
- CarboHyde, Budapest, Berlini u. 47-49, 1045, Hungary; Cyclolab Cyclodextrin Research and Development Ltd., Budapest, Illatos út 7 1097, Hungary
| | | | | | - Ángel Piñeiro
- Departamento de Física Aplicada, Facultade de Física, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; MD.USE Innovative Solutions S.L., Edificio Emprendia, Campus Vida, Santiago de Compostela, Spain
| | - Rebeca García-Fandiño
- Departamento de Química Orgánica, Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, Campus Vida s/n, E-15782 Santiago de Compostela, Spain; MD.USE Innovative Solutions S.L., Edificio Emprendia, Campus Vida, Santiago de Compostela, Spain
| | | |
Collapse
|
3
|
Salem YY, Hoti G, Sammour RMF, Caldera F, Cecone C, Matencio A, Shahiwala AF, Trotta F. Preparation and evaluation of βcyclodextrin-based nanosponges loaded with Budesonide for pulmonary delivery. Int J Pharm 2023; 647:123529. [PMID: 37858636 DOI: 10.1016/j.ijpharm.2023.123529] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2023] [Revised: 10/16/2023] [Accepted: 10/16/2023] [Indexed: 10/21/2023]
Abstract
Budesonide (BUD) is a glucocorticosteroid used to treat chronic obstructive pulmonary disease. Despite this, it is a hydrophobic compound with low bioavailability. To address these hurdles, non-toxic and biocompatible βcyclodextrin-based nanosponges (βCD-NS) were attempted. BUD was loaded on five different βCD-NS at four different ratios. NS with 1,1'-carbonyldiimidazole (CDI) as a crosslinking agent, presented a higher encapsulation efficiency ( ̴ 80%) of BUD at 1:3 BUD: βCD-NS ratio (BUD-βCD-NS). The optimized formulations were characterized by Fourier-transform infrared spectroscopy (FTIR), thermogravimetric analysis (TGA), water absorption capacity (WAC), scanning electron microscopy (SEM), X-ray powder diffraction studies (XRD), particle size, zeta potential, encapsulation efficiency, in vitro and in vivo release studies, acute toxicity study, solid-state characterization, and aerosol performance. In vitro-in vivo correlation and cytotoxicity of the formulations on alveolar cells in vitro were further determined. In vitro and in vivo studies showed almost complete drug release and drug absorption from the lungs in the initial 2 h for pure BUD, which were sustained up to 12 h from BUD loaded into nanosponges (BUD-βCD-NS). Acute toxicity studies and in vitro cytotoxicity studies on alveolar cells proved the safety of BUD-βCD-NS. Several parameters, including particle size, median mass aerodynamic diameter, % fine particle fraction, and % emitted dose, were evaluated for aerosol performance, suggesting the capability of BUD-βCD-NS to formulate as a dry powder inhaler (DPI) with a suitable diluent. To sum up, this research will offer new insights into the future advancement of βCD-NS as drug delivery systems for providing controlled release of therapeutic agents against pulmonary disease.
Collapse
Affiliation(s)
- Yasmein Yaser Salem
- Department of Pharmaceutics, Dubai Pharmacy College for Girls, Al Muhaisanah 1, Al Mizhar, 19099 Dubai, United Arab Emirates.
| | - Gjylije Hoti
- Department of Chemistry, University of Turin, Via P. Giuria 7, 10125 Turin, Italy; Department of Drug Science and Technology, University of Turin, Via P. Giuria 9, 10125 Turin, Italy(1).
| | - Rana M F Sammour
- Department of Pharmaceutics, Dubai Pharmacy College for Girls, Al Muhaisanah 1, Al Mizhar, 19099 Dubai, United Arab Emirates.
| | - Fabrizio Caldera
- Department of Chemistry, University of Turin, Via P. Giuria 7, 10125 Turin, Italy.
| | - Claudio Cecone
- Department of Chemistry, University of Turin, Via P. Giuria 7, 10125 Turin, Italy.
| | - Adrián Matencio
- Department of Chemistry, University of Turin, Via P. Giuria 7, 10125 Turin, Italy.
| | - Aliasgar F Shahiwala
- Department of Pharmaceutics, Dubai Pharmacy College for Girls, Al Muhaisanah 1, Al Mizhar, 19099 Dubai, United Arab Emirates.
| | - Francesco Trotta
- Department of Chemistry, University of Turin, Via P. Giuria 7, 10125 Turin, Italy.
| |
Collapse
|
4
|
de Pablo E, O'Connell P, Fernández-García R, Marchand S, Chauzy A, Tewes F, Dea-Ayuela MA, Kumar D, Bolás F, Ballesteros MP, Torrado JJ, Healy AM, Serrano DR. Targeting lung macrophages for fungal and parasitic pulmonary infections with innovative amphotericin B dry powder inhalers. Int J Pharm 2023; 635:122788. [PMID: 36863544 DOI: 10.1016/j.ijpharm.2023.122788] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2022] [Revised: 02/24/2023] [Accepted: 02/25/2023] [Indexed: 03/04/2023]
Abstract
The incidence of fungal pulmonary infections is known to be on the increase, and yet there is an alarming gap in terms of marketed antifungal therapies that are available for pulmonary administration. Amphotericin B (AmB) is a highly efficient broad-spectrum antifungal only marketed as an intravenous formulation. Based on the lack of effective antifungal and antiparasitic pulmonary treatments, the aim of this study was to develop a carbohydrate-based AmB dry powder inhaler (DPI) formulation, prepared by spray drying. Amorphous AmB microparticles were developed by combining 39.7 % AmB with 39.7 % γ-cyclodextrin, 8.1 % mannose and 12.5 % leucine. An increase in the mannose concentration from 8.1 to 29.8 %, led to partial drug crystallisation. Both formulations showed good in vitro lung deposition characteristics (80 % FPF < 5 µm and MMAD < 3 µm) at different air flow rates (60 and 30 L/min) when used with a DPI, but also during nebulisation upon reconstitution in water.
Collapse
Affiliation(s)
- E de Pablo
- Pharmaceutics and Food Technology Department, School of Pharmacy, Universidad Complutense de Madrid, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain
| | - P O'Connell
- School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin 2, Ireland
| | - R Fernández-García
- Pharmaceutics and Food Technology Department, School of Pharmacy, Universidad Complutense de Madrid, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain
| | - S Marchand
- UMR 1070, Université de PoitiersPôle Biologie Santé, 1, Rue Georges Bonnet, 86073 Poitiers, France; Laboratoire de Toxicologie-Pharmacocinétique, CHU de Poitiers, 2, Rue de la milétrie, 86021 Poitiers, France
| | - A Chauzy
- UMR 1070, Université de PoitiersPôle Biologie Santé, 1, Rue Georges Bonnet, 86073 Poitiers, France
| | - F Tewes
- UMR 1070, Université de PoitiersPôle Biologie Santé, 1, Rue Georges Bonnet, 86073 Poitiers, France; Laboratoire de Toxicologie-Pharmacocinétique, CHU de Poitiers, 2, Rue de la milétrie, 86021 Poitiers, France
| | - M A Dea-Ayuela
- Pharmacy Department, School of Life Sciences, Universidad Cardenal Herrera-CEU, Moncada 46113 Valencia, Spain
| | - D Kumar
- Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi, India
| | - F Bolás
- Parasitology Department, School of Pharmacy, Universidad Complutense de Madrid, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain
| | - M P Ballesteros
- Pharmaceutics and Food Technology Department, School of Pharmacy, Universidad Complutense de Madrid, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain; Instituto Universitario de Farmacia Industrial, Facultad de Farmacia, Universidad Complutense de Madrid, 28040 Madrid, Spain
| | - J J Torrado
- Pharmaceutics and Food Technology Department, School of Pharmacy, Universidad Complutense de Madrid, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain; Instituto Universitario de Farmacia Industrial, Facultad de Farmacia, Universidad Complutense de Madrid, 28040 Madrid, Spain
| | - A M Healy
- School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin 2, Ireland
| | - D R Serrano
- Pharmaceutics and Food Technology Department, School of Pharmacy, Universidad Complutense de Madrid, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain; Instituto Universitario de Farmacia Industrial, Facultad de Farmacia, Universidad Complutense de Madrid, 28040 Madrid, Spain.
| |
Collapse
|
5
|
Nanosized Drug Delivery Systems to Fight Tuberculosis. Pharmaceutics 2023; 15:pharmaceutics15020393. [PMID: 36839715 PMCID: PMC9964171 DOI: 10.3390/pharmaceutics15020393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2022] [Revised: 01/17/2023] [Accepted: 01/20/2023] [Indexed: 01/26/2023] Open
Abstract
Tuberculosis (TB) is currently the second deadliest infectious disease. Existing antitubercular therapies are long, complex, and have severe side effects that result in low patient compliance. In this context, nanosized drug delivery systems (DDSs) have the potential to optimize the treatment's efficiency while reducing its toxicity. Hundreds of publications illustrate the growing interest in this field. In this review, the main challenges related to the use of drug nanocarriers to fight TB are overviewed. Relevant publications regarding DDSs for the treatment of TB are classified according to the encapsulated drugs, from first-line to second-line drugs. The physicochemical and biological properties of the investigated formulations are listed. DDSs could simultaneously (i) optimize the therapy's antibacterial effects; (ii) reduce the doses; (iii) reduce the posology; (iv) diminish the toxicity; and as a global result, (v) mitigate the emergence of resistant strains. Moreover, we highlight that host-directed therapy using nanoparticles (NPs) is a recent promising trend. Although the research on nanosized DDSs for TB treatment is expanding, clinical applications have yet to be developed. Most studies are only dedicated to the development of new formulations, without the in vivo proof of concept. In the near future, it is expected that NPs prepared by "green" scalable methods, with intrinsic antibacterial properties and capable of co-encapsulating synergistic drugs, may find applications to fight TB.
Collapse
|
6
|
Pancani E, Veclani D, Agnes M, Mazza A, Venturini A, Malanga M, Manet I. Three-in-one: exploration of co-encapsulation of cabazitaxel, bicalutamide and chlorin e6 in new mixed cyclodextrin-crosslinked polymers. RSC Adv 2023; 13:10923-10939. [PMID: 37033421 PMCID: PMC10077339 DOI: 10.1039/d3ra01782f] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2023] [Accepted: 03/27/2023] [Indexed: 04/09/2023] Open
Abstract
Three-in-one: a single bCyD polymer easily prepared in water is used to co-encapsulate cabazitaxel and bicalutamide with chlorin e6 affording a nanoplatform to implement multimodal cancer therapy.
Collapse
Affiliation(s)
- Elisabetta Pancani
- Institute for Organic Synthesis and Photoreactivity (ISOF), National Research Council of Italy (CNR), Via P. Gobetti 101, I-40129 Bologna, Italy
| | - Daniele Veclani
- Institute for Organic Synthesis and Photoreactivity (ISOF), National Research Council of Italy (CNR), Via P. Gobetti 101, I-40129 Bologna, Italy
| | - Marco Agnes
- Institute for Organic Synthesis and Photoreactivity (ISOF), National Research Council of Italy (CNR), Via P. Gobetti 101, I-40129 Bologna, Italy
| | - Arianna Mazza
- Institute for Organic Synthesis and Photoreactivity (ISOF), National Research Council of Italy (CNR), Via P. Gobetti 101, I-40129 Bologna, Italy
| | - Alessandro Venturini
- Institute for Organic Synthesis and Photoreactivity (ISOF), National Research Council of Italy (CNR), Via P. Gobetti 101, I-40129 Bologna, Italy
| | - Milo Malanga
- CycloLab, Cyclodextrin R&D Ltd., Budapest, Hungary
| | - Ilse Manet
- Institute for Organic Synthesis and Photoreactivity (ISOF), National Research Council of Italy (CNR), Via P. Gobetti 101, I-40129 Bologna, Italy
| |
Collapse
|
7
|
Topuz F, Uyar T. Advances in the development of cyclodextrin-based nanogels/microgels for biomedical applications: Drug delivery and beyond. Carbohydr Polym 2022; 297:120033. [DOI: 10.1016/j.carbpol.2022.120033] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2022] [Revised: 08/21/2022] [Accepted: 08/22/2022] [Indexed: 12/20/2022]
|
8
|
Agnes M, Pancani E, Malanga M, Fenyvesi E, Manet I. Implementation of Water-Soluble Cyclodextrin-Based Polymers in Biomedical Applications: How Far are we? Macromol Biosci 2022; 22:e2200090. [PMID: 35452159 DOI: 10.1002/mabi.202200090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2022] [Revised: 04/06/2022] [Indexed: 11/10/2022]
Abstract
Cyclodextrin-based polymers can be prepared starting from the naturally occurring monomers following green and low-cost procedures. They can be selectively derivatized pre- or post-polymerization allowing to fine-tune functionalities of ad hoc customized polymers. Preparation nowadays has reached the 100 g scale thanks also to the interest of industries in these extremely versatile compounds. During the last 15 years these macromolecules have been the object of intense investigations in view of possible biomedical applications as the ultimate goal and large amounts of scientific data are now available. Compared to their monomeric models, already used in the formulation of various therapeutic agents, they display superior behavior in terms of their solubility in water and solubilizing power towards drugs incompatible with biological fluids. Moreover, they allow the combination of more than one type of therapeutic agent in the polymeric system. In this review we provide a complete state-of-the-art on the knowledge and potentialities of water-soluble cyclodextrin-based polymers as therapeutic agents as well as carrier systems for different types of therapeutics to implement combination therapy. Finally, we give a perspective on their assets for innovation in disease treatment as well as their limits that still need to be addressed. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Marco Agnes
- Istituto per la Sintesi Organica e la Fotoreattività (ISOF), Consiglio Nazionale delle Ricerche (CNR), via P. Gobetti 101, Bologna, 40129, Italy
| | - Elisabetta Pancani
- Advanced Accelerator Applications, A Novartis Company, via Ribes 5, Ivrea, 10010, Italy
| | - Milo Malanga
- CycloLab, Cyclodextrin R&D Ltd., Budapest, H1097, Hungary
| | - Eva Fenyvesi
- CycloLab, Cyclodextrin R&D Ltd., Budapest, H1097, Hungary
| | - Ilse Manet
- Istituto per la Sintesi Organica e la Fotoreattività (ISOF), Consiglio Nazionale delle Ricerche (CNR), via P. Gobetti 101, Bologna, 40129, Italy
| |
Collapse
|
9
|
Real DA, Bolaños K, Priotti J, Yutronic N, Kogan MJ, Sierpe R, Donoso-González O. Cyclodextrin-Modified Nanomaterials for Drug Delivery: Classification and Advances in Controlled Release and Bioavailability. Pharmaceutics 2021; 13:2131. [PMID: 34959412 PMCID: PMC8706493 DOI: 10.3390/pharmaceutics13122131] [Citation(s) in RCA: 35] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2021] [Revised: 12/01/2021] [Accepted: 12/03/2021] [Indexed: 12/18/2022] Open
Abstract
In drug delivery, one widely used way of overcoming the biopharmaceutical problems present in several active pharmaceutical ingredients, such as poor aqueous solubility, early instability, and low bioavailability, is the formation of inclusion compounds with cyclodextrins (CD). In recent years, the use of CD derivatives in combination with nanomaterials has shown to be a promising strategy for formulating new, optimized systems. The goals of this review are to give in-depth knowledge and critical appraisal of the main CD-modified or CD-based nanomaterials for drug delivery, such as lipid-based nanocarriers, natural and synthetic polymeric nanocarriers, nanosponges, graphene derivatives, mesoporous silica nanoparticles, plasmonic and magnetic nanoparticles, quantum dots and other miscellaneous systems such as nanovalves, metal-organic frameworks, Janus nanoparticles, and nanofibers. Special attention is given to nanosystems that achieve controlled drug release and increase their bioavailability during in vivo studies.
Collapse
Affiliation(s)
- Daniel Andrés Real
- Laboratorio de Nanobiotecnología y Nanotoxicología, Departamento de Química Farmacológica y Toxicológica, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago 8380544, Chile; (D.A.R.); (K.B.); (M.J.K.)
- Advanced Center for Chronic Diseases (ACCDiS), Universidad de Chile and Pontificia Universidad Católica de Chile, Santiago 8380544, Chile
| | - Karen Bolaños
- Laboratorio de Nanobiotecnología y Nanotoxicología, Departamento de Química Farmacológica y Toxicológica, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago 8380544, Chile; (D.A.R.); (K.B.); (M.J.K.)
- Advanced Center for Chronic Diseases (ACCDiS), Universidad de Chile and Pontificia Universidad Católica de Chile, Santiago 8380544, Chile
- Cellular Communication Laboratory, Program of Cellular and Molecular Biology, Center for Studies on Exercise, Metabolism and Cancer (CEMC), Facultad de Medicina, Instituto de Ciencias Biomédicas, Universidad de Chile, Santiago 8380453, Chile
| | - Josefina Priotti
- Área Técnica Farmacéutica, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Rosario S2002LRK, Argentina;
| | - Nicolás Yutronic
- Laboratorio de Nanoquímica y Química Supramolecular, Departamento de Química, Facultad de Ciencias, Universidad de Chile, Santiago 7800003, Chile;
| | - Marcelo J. Kogan
- Laboratorio de Nanobiotecnología y Nanotoxicología, Departamento de Química Farmacológica y Toxicológica, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago 8380544, Chile; (D.A.R.); (K.B.); (M.J.K.)
- Advanced Center for Chronic Diseases (ACCDiS), Universidad de Chile and Pontificia Universidad Católica de Chile, Santiago 8380544, Chile
| | - Rodrigo Sierpe
- Laboratorio de Nanobiotecnología y Nanotoxicología, Departamento de Química Farmacológica y Toxicológica, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago 8380544, Chile; (D.A.R.); (K.B.); (M.J.K.)
- Advanced Center for Chronic Diseases (ACCDiS), Universidad de Chile and Pontificia Universidad Católica de Chile, Santiago 8380544, Chile
- Laboratorio de Nanoquímica y Química Supramolecular, Departamento de Química, Facultad de Ciencias, Universidad de Chile, Santiago 7800003, Chile;
- Laboratorio de Biosensores, Departamento de Química Farmacológica y Toxicológica, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago 8380494, Chile
| | - Orlando Donoso-González
- Laboratorio de Nanobiotecnología y Nanotoxicología, Departamento de Química Farmacológica y Toxicológica, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago 8380544, Chile; (D.A.R.); (K.B.); (M.J.K.)
- Advanced Center for Chronic Diseases (ACCDiS), Universidad de Chile and Pontificia Universidad Católica de Chile, Santiago 8380544, Chile
- Laboratorio de Nanoquímica y Química Supramolecular, Departamento de Química, Facultad de Ciencias, Universidad de Chile, Santiago 7800003, Chile;
| |
Collapse
|
10
|
Cyclodextrin Polymers as Delivery Systems for Targeted Anti-Cancer Chemotherapy. Molecules 2021; 26:molecules26196046. [PMID: 34641590 PMCID: PMC8512365 DOI: 10.3390/molecules26196046] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2021] [Revised: 09/28/2021] [Accepted: 09/29/2021] [Indexed: 12/09/2022] Open
Abstract
In the few last years, nanosystems have emerged as a potential therapeutic approach to improve the efficacy and selectivity of many drugs. Cyclodextrins (CyDs) and their nanoparticles have been widely investigated as drug delivery systems. The covalent functionalization of CyD polymer nanoparticles with targeting molecules can improve the therapeutic potential of this family of nanosystems. In this study, we investigated cross-linked γ- and β-cyclodextrin polymers as carriers for doxorubicin (ox) and oxaliplatin (Oxa). We also functionalized γ-CyD polymer bearing COOH functionalities with arginine-glycine-aspartic or arginine moieties for targeting the integrin receptors of cancer cells. We tested the Dox and Oxa anti-proliferative activity in the presence of the precursor polymer with COOH functionalities and its derivatives in A549 (lung, carcinoma) and HepG2 (liver, carcinoma) cell lines. We found that CyD polymers can significantly improve the antiproliferative activity of Dox in HepG2 cell lines only, whereas the cytotoxic activity of Oxa resulted as enhanced in both cell lines. The peptide or amino acid functionalized CyD polymers, loaded with Dox, did not show any additional effect compared to the precursor polymer. Finally, studies of Dox uptake showed that the higher antiproliferative activity of complexes correlates with the higher accumulation of Dox inside the cells. The results show that CyD polymers could be used as carriers for repositioning classical anticancer drugs such as Dox or Oxa to increase their antitumor activity.
Collapse
|
11
|
Repurposing Bedaquiline for Effective Non-Small Cell Lung Cancer (NSCLC) Therapy as Inhalable Cyclodextrin-Based Molecular Inclusion Complexes. Int J Mol Sci 2021; 22:ijms22094783. [PMID: 33946414 PMCID: PMC8124211 DOI: 10.3390/ijms22094783] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2021] [Revised: 04/20/2021] [Accepted: 04/28/2021] [Indexed: 12/13/2022] Open
Abstract
There is growing evidence that repurposed drugs demonstrate excellent efficacy against many cancers, while facilitating accelerated drug development process. In this study, bedaquiline (BDQ), an FDA approved anti-mycobacterial agent, was repurposed and an inhalable cyclodextrin complex formulation was developed to explore its anti-cancer activity in non-small cell lung cancer (NSCLC). A sulfobutyl ether derivative of β-cyclodextrin (SBE-β-CD) was selected based on phase solubility studies and molecular modeling to prepare an inclusion complex of BDQ and cyclodextrin. Aqueous solubility of BDQ was increased by 2.8 × 103-fold after complexation with SBE-β-CD, as compared to its intrinsic solubility. Solid-state characterization studies confirmed the successful incorporation of BDQ in the SBE-β-CD cavity. In vitro lung deposition study results demonstrated excellent inhalable properties (mass median aerodynamic diameter: 2.9 ± 0.6 µm (<5 µm) and fine particle fraction: 83.3 ± 3.8%) of BDQ-CD complex. Accelerated stability studies showed BDQ-CD complex to be stable up to 3 weeks. From cytotoxicity studies, a slight enhancement in the anti-cancer efficacy was observed with BDQ-cyclodextrin complex, compared to BDQ alone in H1299 cell line. The IC50 values for BDQ and BDQ-CD complex were found to be ~40 µM in case of H1299 cell line at 72 h, whereas BDQ/BDQ-CD were not found to be cytotoxic up to concentrations of 50 µM in A549 cell line. Taken together, BDQ-CD complex offers a promising inhalation strategy with efficient lung deposition and cytotoxicity for NSCLC treatment.
Collapse
|
12
|
Möller K, Macaulay B, Bein T. Curcumin Encapsulated in Crosslinked Cyclodextrin Nanoparticles Enables Immediate Inhibition of Cell Growth and Efficient Killing of Cancer Cells. NANOMATERIALS (BASEL, SWITZERLAND) 2021; 11:489. [PMID: 33672006 PMCID: PMC7919290 DOI: 10.3390/nano11020489] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/18/2021] [Revised: 02/04/2021] [Accepted: 02/05/2021] [Indexed: 12/12/2022]
Abstract
The efficiency of anti-cancer drugs is commonly determined by endpoint assays after extended incubation times, often after days. Here we demonstrate that curcumin encapsulated in crosslinked cyclodextrin nanoparticles (CD-NP) acts extremely rapidly on cell metabolism resulting in an immediate and complete inhibition of cell growth and in efficient cancer-cell killing only few hours after incubation. This early onset of anti-cancer action was discovered by live-cell high-throughput fluorescence microscopy using an environmental stage. To date, only very few examples of covalently crosslinked nanoscale CD-based (CD-NP) drug carriers exist. Crosslinking cyclodextrins enables the adsorption of unusually high payloads of hydrophobic curcumin (762 µg CC/mg CD-NP) reflecting a molar ratio of 2.3:1 curcumin to cyclodextrin. We have investigated the effect of CD-NP encapsulated curcumin (CD-CC-NP) in comparison to free, DMSO-derived curcumin nanoparticles (CC-NP) on 4 different cell lines. Very short incubations times as low as 1 h were applied and cell responses after medium change were subsequently followed over two days. We show that cell proliferation is inhibited nearly immediately in all cell lines and that a cell- and concentration dependent cancer-cell killing occurs. Anti-cancer effects were similar with free and encapsulated curcumin, however, encapsulation in CD-NP drastically extends the long-term photostability and anti-cancer activity of curcumin. Curcumin-sensitivity is highest in HeLa cells reaching up to 90% cell death under these conditions. Sensitivity decreased from HeLa to T24 to MDA MB-231 cells. Strikingly, the immortalized non-cancerous cell line MCF-10A was robust against curcumin concentrations that were highly toxic to the other cell lines. Our results underline the potential of curcumin as gentle and yet effective natural anti-cancer agent when delivered solvent-free in stabilizing and biocompatible drug carriers such as CD-NP that enable efficient cellular delivery.
Collapse
Affiliation(s)
- Karin Möller
- Department of Chemistry and Center for NanoScience, University of Munich (LMU), Butenandtstrasse 5–13, 81377 Munich, Germany;
| | | | - Thomas Bein
- Department of Chemistry and Center for NanoScience, University of Munich (LMU), Butenandtstrasse 5–13, 81377 Munich, Germany;
| |
Collapse
|
13
|
Sánchez A, Mejía SP, Orozco J. Recent Advances in Polymeric Nanoparticle-Encapsulated Drugs against Intracellular Infections. Molecules 2020; 25:E3760. [PMID: 32824757 PMCID: PMC7464666 DOI: 10.3390/molecules25163760] [Citation(s) in RCA: 41] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2020] [Revised: 07/31/2020] [Accepted: 08/11/2020] [Indexed: 02/07/2023] Open
Abstract
Polymeric nanocarriers (PNs) have demonstrated to be a promising alternative to treat intracellular infections. They have outstanding performance in delivering antimicrobials intracellularly to reach an adequate dose level and improve their therapeutic efficacy. PNs offer opportunities for preventing unwanted drug interactions and degradation before reaching the target cell of tissue and thus decreasing the development of resistance in microorganisms. The use of PNs has the potential to reduce the dose and adverse side effects, providing better efficiency and effectiveness of therapeutic regimens, especially in drugs having high toxicity, low solubility in the physiological environment and low bioavailability. This review provides an overview of nanoparticles made of different polymeric precursors and the main methodologies to nanofabricate platforms of tuned physicochemical and morphological properties and surface chemistry for controlled release of antimicrobials in the target. It highlights the versatility of these nanosystems and their challenges and opportunities to deliver antimicrobial drugs to treat intracellular infections and mentions nanotoxicology aspects and future outlooks.
Collapse
Affiliation(s)
- Arturo Sánchez
- Max Planck Tandem Group in Nanobioengineering, University of Antioquia, Complejo Ruta N, Calle 67 Nº 52-20, Medellín 050010, Colombia; (A.S.); (S.P.M.)
| | - Susana P. Mejía
- Max Planck Tandem Group in Nanobioengineering, University of Antioquia, Complejo Ruta N, Calle 67 Nº 52-20, Medellín 050010, Colombia; (A.S.); (S.P.M.)
- Experimental and Medical Micology Group, Corporación para Investigaciones Biológicas (CIB), Carrera, 72A Nº 78B–141 Medellín 050010, Colombia
| | - Jahir Orozco
- Max Planck Tandem Group in Nanobioengineering, University of Antioquia, Complejo Ruta N, Calle 67 Nº 52-20, Medellín 050010, Colombia; (A.S.); (S.P.M.)
| |
Collapse
|
14
|
Villemagne B, Machelart A, Tran NC, Flipo M, Moune M, Leroux F, Piveteau C, Wohlkönig A, Wintjens R, Li X, Gref R, Brodin P, Deprez B, Baulard AR, Willand N. Fragment-Based Optimized EthR Inhibitors with in Vivo Ethionamide Boosting Activity. ACS Infect Dis 2020; 6:366-378. [PMID: 32011115 DOI: 10.1021/acsinfecdis.9b00277] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Killing more than one million people each year, tuberculosis remains the leading cause of death from a single infectious agent. The growing threat of multidrug-resistant strains of Mycobacterium tuberculosis stresses the need for alternative therapies. EthR, a mycobacterial transcriptional regulator, is involved in the control of the bioactivation of the second-line drug ethionamide. We have previously reported the discovery of in vitro nanomolar boosters of ethionamide through fragment-based approaches. In this study, we have further explored the structure-activity and structure-property relationships in this chemical family. By combining structure-based drug design and in vitro evaluation of the compounds, we identified a new oxadiazole compound as the first fragment-based ethionamide booster which proved to be active in vivo, in an acute model of tuberculosis infection.
Collapse
Affiliation(s)
- Baptiste Villemagne
- Univ. Lille, Inserm, Institut Pasteur de Lille, U1177—Drugs and Molecules for Living Systems, F-59000 Lille, France
| | - Arnaud Machelart
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR8204-CIIL−Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Ngoc Chau Tran
- Univ. Lille, Inserm, Institut Pasteur de Lille, U1177—Drugs and Molecules for Living Systems, F-59000 Lille, France
| | - Marion Flipo
- Univ. Lille, Inserm, Institut Pasteur de Lille, U1177—Drugs and Molecules for Living Systems, F-59000 Lille, France
| | - Martin Moune
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR8204-CIIL−Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Florence Leroux
- Univ. Lille, Inserm, Institut Pasteur de Lille, U1177—Drugs and Molecules for Living Systems, F-59000 Lille, France
| | - Catherine Piveteau
- Univ. Lille, Inserm, Institut Pasteur de Lille, U1177—Drugs and Molecules for Living Systems, F-59000 Lille, France
| | - Alexandre Wohlkönig
- Structural Biology Brussels and Molecular and Cellular Interactions, Vrije Universiteit Brussel, 1050 Brussels, Belgium
- VIB-VUB Center for Structural Biology, VIB, Brussels, Belgium
| | - René Wintjens
- Unité Microbiologie, Chimie bioorganique et Macromoléculaire (CP206/04), Institut de Pharmacie, Université Libre de Bruxelles, 1050 Brussels, Belgium
| | - Xue Li
- Institut des Sciences Moléculaires d’Orsay, UMR CNRS 8214, Université Paris-Sud, Université Paris Saclay, 91400 Orsay, France
| | - Ruxandra Gref
- Institut des Sciences Moléculaires d’Orsay, UMR CNRS 8214, Université Paris-Sud, Université Paris Saclay, 91400 Orsay, France
| | - Priscille Brodin
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR8204-CIIL−Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Benoit Deprez
- Univ. Lille, Inserm, Institut Pasteur de Lille, U1177—Drugs and Molecules for Living Systems, F-59000 Lille, France
| | - Alain R Baulard
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR8204-CIIL−Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Nicolas Willand
- Univ. Lille, Inserm, Institut Pasteur de Lille, U1177—Drugs and Molecules for Living Systems, F-59000 Lille, France
| |
Collapse
|
15
|
Gadade DD, Pekamwar SS. Cyclodextrin Based Nanoparticles for Drug Delivery and Theranostics. Adv Pharm Bull 2020; 10:166-183. [PMID: 32373486 PMCID: PMC7191229 DOI: 10.34172/apb.2020.022] [Citation(s) in RCA: 58] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2019] [Revised: 08/29/2019] [Accepted: 10/01/2019] [Indexed: 12/18/2022] Open
Abstract
Colloidal nanoparticulate technology has been described in the literature as a versatile drug delivery system. But it possesses some inherent lacunae in their formulation. Cyclodextrins (CDs) have been extensively reported for the solubility enhancement of poorly water-soluble drugs. The CDs can cause intervention in aspects related to nanoparticles (NPs) that include improving drug loading in nano-system, improving stability, site-specific/targeted drug delivery, improving solubility profile and absorption of the drug in nanosystem with consequent improvement in bioavailability, with the possibility of controlled release, safety and efficacy. They find application in for simultaneous diagnosis and therapeutics for better treatment procedures. The current communication is focused on the application of CDs to overcome troubles in nanoparticulate formulation and enhancement of their performance. It also envisages the theranostic aspects of CDs.
Collapse
Affiliation(s)
- Dipak Dilip Gadade
- Department of Pharmaceutics, Shri Bhagwan College of Pharmacy, CIDCO, N-6, Dr. Y.S. Khedkar Marg, Aurangabad-431001, India.,School of Pharmacy, SRTM University,Vishnupuri, Nanded- 431606, India
| | | |
Collapse
|
16
|
Pastor A, Machelart A, Li X, Willand N, Baulard A, Brodin P, Gref R, Desmaële D. A novel codrug made of the combination of ethionamide and its potentiating booster: synthesis, self-assembly into nanoparticles and antimycobacterial evaluation. Org Biomol Chem 2019; 17:5129-5137. [PMID: 31073555 DOI: 10.1039/c9ob00680j] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Ethionamide (ETH) is one of the most widely used second-line chemotherapeutic drugs for the treatment of multi-drug-resistant tuberculosis. The bioactivation and activity of ETH is dramatically potentiated by a family of molecules called "boosters" among which BDM43266 is one of the most potent. However, the co-administration of these active molecules is hampered by their low solubility in biological media and by the strong tendency of ETH to crystallize. A novel strategy that involves synthesizing a codrug able to self-associate into nanoparticles prone to be taken up by infected macrophages is proposed here. This codrug is designed by tethering N-hydroxymethyl derivatives of both ETH and its booster through a glutaric linker. This codrug self-assembles into nanoparticles of around 200 nm, stable upon extreme dilution without disaggregating as well as upon concentration. The nanoparticles of the codrug can be intranasally administered overcoming the unfavorable physico-chemical profiles of the parent drugs. Intrapulmonary delivery of the codrug nanoparticles to Mtb infected mice via the intranasal route at days 7, 9, 11, 14, 16 and 18 post-infection reduces the bacterial load in the lungs by a factor of 6.
Collapse
Affiliation(s)
- Alexandra Pastor
- Institut Galien Paris-Sud, UMR 8612, CNRS, Université Paris-Sud, Faculté de Pharmacie, 5 rue JB Clément, 92296 Châtenay-Malabry, France.
| | - Arnaud Machelart
- Université de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR8204 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Xue Li
- Institute of Molecular Sciences, UMR CNRS 8214, Université Paris-Sud, 91400 Orsay, France
| | - Nicolas Willand
- Université de Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living Systems, F-59000 Lille, France
| | - Alain Baulard
- Université de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR8204 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Priscille Brodin
- Université de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR8204 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Ruxandra Gref
- Institute of Molecular Sciences, UMR CNRS 8214, Université Paris-Sud, 91400 Orsay, France
| | - Didier Desmaële
- Institut Galien Paris-Sud, UMR 8612, CNRS, Université Paris-Sud, Faculté de Pharmacie, 5 rue JB Clément, 92296 Châtenay-Malabry, France.
| |
Collapse
|
17
|
Machelart A, Salzano G, Li X, Demars A, Debrie AS, Menendez-Miranda M, Pancani E, Jouny S, Hoffmann E, Deboosere N, Belhaouane I, Rouanet C, Simar S, Talahari S, Giannini V, Villemagne B, Flipo M, Brosch R, Nesslany F, Deprez B, Muraille E, Locht C, Baulard AR, Willand N, Majlessi L, Gref R, Brodin P. Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis. ACS NANO 2019; 13:3992-4007. [PMID: 30822386 PMCID: PMC6718168 DOI: 10.1021/acsnano.8b07902] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/16/2018] [Accepted: 03/01/2019] [Indexed: 05/23/2023]
Abstract
Multi-drug-resistant tuberculosis (TB) is a major public health problem, concerning about half a million cases each year. Patients hardly adhere to the current strict treatment consisting of more than 10 000 tablets over a 2-year period. There is a clear need for efficient and better formulated medications. We have previously shown that nanoparticles made of cross-linked poly-β-cyclodextrins (pβCD) are efficient vehicles for pulmonary delivery of powerful combinations of anti-TB drugs. Here, we report that in addition to being efficient drug carriers, pβCD nanoparticles are endowed with intrinsic antibacterial properties. Empty pβCD nanoparticles are able to impair Mycobacterium tuberculosis (Mtb) establishment after pulmonary administration in mice. pβCD hamper colonization of macrophages by Mtb by interfering with lipid rafts, without inducing toxicity. Moreover, pβCD provoke macrophage apoptosis, leading to depletion of infected cells, thus creating a lung microenvironment detrimental to Mtb persistence. Taken together, our results suggest that pβCD nanoparticles loaded or not with antibiotics have an antibacterial action on their own and could be used as a carrier in drug regimen formulations effective against TB.
Collapse
Affiliation(s)
- Arnaud Machelart
- Université
de Lille, CNRS, INSERM, CHU Lille, Institut
Pasteur de Lille, U1019 - UMR 8204 - CIIL
- Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Giuseppina Salzano
- Université
Paris Sud, Université Paris-Saclay, CNRS, UMR 8214 - Institute for Molecular Sciences of Orsay (ISMO), F-91405 Orsay, France
| | - Xue Li
- Université
Paris Sud, Université Paris-Saclay, CNRS, UMR 8214 - Institute for Molecular Sciences of Orsay (ISMO), F-91405 Orsay, France
| | - Aurore Demars
- Research
Unit in Microorganisms Biology (URBM), Laboratory of Immunology and
Microbiology, Université de Namur, Narilis, B-5000 Namur, Belgium
| | - Anne-Sophie Debrie
- Université
de Lille, CNRS, INSERM, CHU Lille, Institut
Pasteur de Lille, U1019 - UMR 8204 - CIIL
- Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Mario Menendez-Miranda
- Université
Paris Sud, Université Paris-Saclay, CNRS, UMR 8214 - Institute for Molecular Sciences of Orsay (ISMO), F-91405 Orsay, France
| | - Elisabetta Pancani
- Université
Paris Sud, Université Paris-Saclay, CNRS, UMR 8214 - Institute for Molecular Sciences of Orsay (ISMO), F-91405 Orsay, France
| | - Samuel Jouny
- Université
de Lille, CNRS, INSERM, CHU Lille, Institut
Pasteur de Lille, U1019 - UMR 8204 - CIIL
- Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Eik Hoffmann
- Université
de Lille, CNRS, INSERM, CHU Lille, Institut
Pasteur de Lille, U1019 - UMR 8204 - CIIL
- Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Nathalie Deboosere
- Université
de Lille, CNRS, INSERM, CHU Lille, Institut
Pasteur de Lille, U1019 - UMR 8204 - CIIL
- Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Imène Belhaouane
- Université
de Lille, CNRS, INSERM, CHU Lille, Institut
Pasteur de Lille, U1019 - UMR 8204 - CIIL
- Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Carine Rouanet
- Université
de Lille, CNRS, INSERM, CHU Lille, Institut
Pasteur de Lille, U1019 - UMR 8204 - CIIL
- Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Sophie Simar
- Université
de Lille, Institut Pasteur de Lille, EA 4483, F-59000 Lille, France
| | - Smaïl Talahari
- Université
de Lille, Institut Pasteur de Lille, EA 4483, F-59000 Lille, France
| | - Valerie Giannini
- Institut
Pasteur, Unit for Integrated
Mycobacterial Pathogenomics, Paris, CNRS
UMR 3525, 25 Rue du Dr. Roux, F-75015 Paris, France
| | - Baptiste Villemagne
- Université
de Lille, INSERM, Institut Pasteur de Lille, U1177 - Drugs and Molecules for living Systems, F-59000 Lille, France
| | - Marion Flipo
- Université
de Lille, INSERM, Institut Pasteur de Lille, U1177 - Drugs and Molecules for living Systems, F-59000 Lille, France
| | - Roland Brosch
- Institut
Pasteur, Unit for Integrated
Mycobacterial Pathogenomics, Paris, CNRS
UMR 3525, 25 Rue du Dr. Roux, F-75015 Paris, France
| | - Fabrice Nesslany
- Université
de Lille, Institut Pasteur de Lille, EA 4483, F-59000 Lille, France
| | - Benoit Deprez
- Université
de Lille, INSERM, Institut Pasteur de Lille, U1177 - Drugs and Molecules for living Systems, F-59000 Lille, France
| | - Eric Muraille
- Research
Unit in Microorganisms Biology (URBM), Laboratory of Immunology and
Microbiology, Université de Namur, Narilis, B-5000 Namur, Belgium
- Laboratory
of Parasitology, Faculty of Medicine, Université
Libre de Bruxelles, B-1070 Brussels, Belgium
| | - Camille Locht
- Université
de Lille, CNRS, INSERM, CHU Lille, Institut
Pasteur de Lille, U1019 - UMR 8204 - CIIL
- Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Alain R. Baulard
- Université
de Lille, CNRS, INSERM, CHU Lille, Institut
Pasteur de Lille, U1019 - UMR 8204 - CIIL
- Center for Infection and Immunity of Lille, F-59000 Lille, France
| | - Nicolas Willand
- Université
de Lille, INSERM, Institut Pasteur de Lille, U1177 - Drugs and Molecules for living Systems, F-59000 Lille, France
| | - Laleh Majlessi
- Institut
Pasteur, Unit for Integrated
Mycobacterial Pathogenomics, Paris, CNRS
UMR 3525, 25 Rue du Dr. Roux, F-75015 Paris, France
| | - Ruxandra Gref
- Université
Paris Sud, Université Paris-Saclay, CNRS, UMR 8214 - Institute for Molecular Sciences of Orsay (ISMO), F-91405 Orsay, France
| | - Priscille Brodin
- Université
de Lille, CNRS, INSERM, CHU Lille, Institut
Pasteur de Lille, U1019 - UMR 8204 - CIIL
- Center for Infection and Immunity of Lille, F-59000 Lille, France
| |
Collapse
|
18
|
Wankar J, Bonvicini F, Benkovics G, Marassi V, Malanga M, Fenyvesi E, Gentilomi GA, Reschiglian P, Roda B, Manet I. Widening the Therapeutic Perspectives of Clofazimine by Its Loading in Sulfobutylether β-Cyclodextrin Nanocarriers: Nanomolar IC50 Values against MDR S. epidermidis. Mol Pharm 2018; 15:3823-3836. [DOI: 10.1021/acs.molpharmaceut.8b00321] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Jitendra Wankar
- Istituto per la Sintesi Organica e la Fotoreattività (ISOF), Consiglio Nazionale delle Ricerche (CNR), via P. Gobetti 101, 40129 Bologna, Italy
| | - Francesca Bonvicini
- Department of Pharmacy and Biotechnology, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
| | | | - Valentina Marassi
- Department of Chemistry “G. Ciamician”, Via Selmi 2, 40126 Bologna, Italy
- byFlow Srl, Via Caduti della Via Fani 11/b, 40127 Bologna, Italy
| | - Milo Malanga
- CycloLab, Cyclodextrin R&D Ltd., H1097 Budapest, Hungary
| | - Eva Fenyvesi
- CycloLab, Cyclodextrin R&D Ltd., H1097 Budapest, Hungary
| | - Giovanna Angela Gentilomi
- Department of Pharmacy and Biotechnology, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
- Microbiology Unit, St Orsola Malpighi University Hospital, Via Massarenti 9, 40138 Bologna, Italy
| | - Pierluigi Reschiglian
- Department of Chemistry “G. Ciamician”, Via Selmi 2, 40126 Bologna, Italy
- byFlow Srl, Via Caduti della Via Fani 11/b, 40127 Bologna, Italy
| | - Barbara Roda
- Department of Chemistry “G. Ciamician”, Via Selmi 2, 40126 Bologna, Italy
- byFlow Srl, Via Caduti della Via Fani 11/b, 40127 Bologna, Italy
| | - Ilse Manet
- Istituto per la Sintesi Organica e la Fotoreattività (ISOF), Consiglio Nazionale delle Ricerche (CNR), via P. Gobetti 101, 40129 Bologna, Italy
| |
Collapse
|
19
|
Abbadi BL, Rodrigues-Junior VDS, Dadda ADS, Pissinate K, Villela AD, Campos MM, Lopes LGDF, Bizarro CV, Machado P, Sousa EHS, Basso LA. Is IQG-607 a Potential Metallodrug or Metallopro-Drug With a Defined Molecular Target in Mycobacterium tuberculosis? Front Microbiol 2018; 9:880. [PMID: 29765372 PMCID: PMC5938375 DOI: 10.3389/fmicb.2018.00880] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2018] [Accepted: 04/16/2018] [Indexed: 12/14/2022] Open
Abstract
The emergence of strains of Mycobacterium tuberculosis resistant to isoniazid (INH) has underscored the need for the development of new anti-tuberculosis agents. INH is activated by the mycobacterial katG-encoded catalase-peroxidase, forming an acylpyridine fragment that is covalently attached to the C4 of NADH. This isonicotinyl-NAD adduct inhibits the activity of 2-trans-enoyl-ACP(CoA) reductase (InhA), which plays a role in mycolic acid biosynthesis. A metal-based INH analog, Na3[FeII(CN)5(INH)]·4H2O, IQG-607, was designed to have an electronic redistribution on INH moiety that would lead to an intramolecular electron transfer to bypass KatG activation. HPLC and EPR studies showed that the INH moiety can be oxidized by superoxide or peroxide yielding similar metabolites and isonicotinoyl radical only when associated to IQG-607, thereby supporting redox-mediated drug activation as a possible mechanism of action. However, IQG-607 was shown to inhibit the in vitro activity of both wild-type and INH-resistant mutant InhA enzymes in the absence of KatG activation. IQG-607 given by the oral route to M. tuberculosis-infected mice reduced lung lesions. Experiments using early and late controls of infection revealed a bactericidal activity for IQG-607. HPLC and voltammetric methods were developed to quantify IQG-607. Pharmacokinetic studies showed short half-life, high clearance, moderate volume of distribution, and low oral bioavailability, which was not altered by feeding. Safety and toxic effects of IQG-607 after acute and 90-day repeated oral administrations in both rats and minipigs showed occurrence of mild to moderate toxic events. Eight multidrug-resistant strains (MDR-TB) were resistant to IQG-607, suggesting an association between katG mutation and increasing MIC values. Whole genome sequencing of three spontaneous IQG-607-resistant strains harbored katG gene mutations. MIC measurements and macrophage infection experiments with a laboratorial strain showed that katG mutation is sufficient to confer resistance to IQG-607 and that the macrophage intracellular environment cannot trigger the self-activation mechanism. Reduced activity of IQG-607 against an M. tuberculosis strain overexpressing S94A InhA mutant protein suggested both the need for KatG activation and InhA as its target. Further efforts are suggested to be pursued toward attempting to translate IQG-607 into a chemotherapeutic agent to treat tuberculosis.
Collapse
Affiliation(s)
- Bruno L Abbadi
- Centro de Pesquisas em Biologia Molecular e Funcional, Instituto Nacional de Ciência e Tecnologia em Tuberculose, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil.,Programa de Pós-Graduação em Biologia Celular e Molecular, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil
| | - Valnês da Silva Rodrigues-Junior
- Centro de Pesquisas em Biologia Molecular e Funcional, Instituto Nacional de Ciência e Tecnologia em Tuberculose, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil
| | - Adilio da Silva Dadda
- Centro de Pesquisas em Biologia Molecular e Funcional, Instituto Nacional de Ciência e Tecnologia em Tuberculose, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil.,Programa de Pós-Graduação em Biologia Celular e Molecular, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil
| | - Kenia Pissinate
- Centro de Pesquisas em Biologia Molecular e Funcional, Instituto Nacional de Ciência e Tecnologia em Tuberculose, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil
| | - Anne D Villela
- Centro de Pesquisas em Biologia Molecular e Funcional, Instituto Nacional de Ciência e Tecnologia em Tuberculose, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil
| | - Maria M Campos
- Centro de Pesquisas em Biologia Molecular e Funcional, Instituto Nacional de Ciência e Tecnologia em Tuberculose, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil.,Programa de Pós-Graduação em Medicina e Ciências da Saúde, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil
| | - Luiz G de França Lopes
- Grupo de Bioinorgânica, Departamento de Química Orgânica e Inorgânica, Universidade Federal do Ceará, Fortaleza, Brazil
| | - Cristiano V Bizarro
- Centro de Pesquisas em Biologia Molecular e Funcional, Instituto Nacional de Ciência e Tecnologia em Tuberculose, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil.,Programa de Pós-Graduação em Biologia Celular e Molecular, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil
| | - Pablo Machado
- Centro de Pesquisas em Biologia Molecular e Funcional, Instituto Nacional de Ciência e Tecnologia em Tuberculose, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil.,Programa de Pós-Graduação em Biologia Celular e Molecular, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil
| | - Eduardo H S Sousa
- Grupo de Bioinorgânica, Departamento de Química Orgânica e Inorgânica, Universidade Federal do Ceará, Fortaleza, Brazil
| | - Luiz A Basso
- Centro de Pesquisas em Biologia Molecular e Funcional, Instituto Nacional de Ciência e Tecnologia em Tuberculose, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil.,Programa de Pós-Graduação em Biologia Celular e Molecular, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil.,Programa de Pós-Graduação em Medicina e Ciências da Saúde, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil
| |
Collapse
|
20
|
Recent therapeutic approaches for the management of tuberculosis: Challenges and opportunities. Biomed Pharmacother 2018; 99:735-745. [DOI: 10.1016/j.biopha.2018.01.115] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2017] [Revised: 01/23/2018] [Accepted: 01/24/2018] [Indexed: 11/19/2022] Open
|